Intravital imaging and cavitation monitoring of antivascular ultrasound in tumor microvasculature

Xiaoxiao Zhao1,2*, Carly Pellow2*, David E. Goertz1,2*

1. Department of Medical Biophysics, University of Toronto, Canada.
2. Sunnybrook Research Institute, Toronto, Canada.

*These authors contributed equally to this work.

© The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/).

Abstract

Rationale: Focused ultrasound-stimulated microbubbles have been shown to be capable of inducing blood flow shutdown and necrosis in a range of tissue types in an approach termed antivascular ultrasound or nonthermal ablation. In oncology, this approach has demonstrated tumor growth inhibition, and profound synergistic antitumor effects when combined with traditional platforms of chemo-, radiation- and immune-therapies. However, the exposure schemes employed have been broad and underlying mechanisms remain unclear with fundamental questions about exposures, vessel types and sizes involved, and the nature of bubble behaviors and their acoustic emissions resulting in vascular damage – impeding the establishment of standard protocols.

Methods: Here, ultrasound transmitters and receivers are integrated into a murine dorsal window chamber tumor model for intravital microscopy studies capable of real-time visual and acoustic monitoring during antivascular ultrasound. Vessel type (normal and tumor-affected), caliber, and viability are assessed under higher pressure conditions (1, 2, and 3 MPa), and cavitation signatures are linked to the biological effects.

Results: Vascular events occurred preferentially in tumor-affected vessels with greater incidence in smaller vessels and with more severity as a function of increasing pressure. Vascular blood flow shutdown was found to be due to a combination of focal disruption events and network-related flow changes. Acoustic emissions displayed elevated broadband noise and distinct sub- and ultra-harmonics and their associated third-order peaks with increasing pressure.

Conclusions: The observed vascular events taken collectively with identified cavitation signatures provide an improved mechanistic understanding of antivascular ultrasound at the microscale, with implications for establishing a specific treatment protocol and control platform.

Key words: antivascular ultrasound, cavitation, mechanical ablation, microbubble, intravital imaging

Introduction

Therapeutic focused ultrasound (FUS) is rapidly emerging as a tool to noninvasively induce controlled and targeted biological effects. FUS has the potential to impact a wide range of clinical applications, including the treatment of tumors. While a range of ultrasound methods can be employed, a prominent approach involves the use of exogenous microbubbles (MBs) in the blood stream, which are focally stimulated by FUS. The premise of MB-mediated therapy is that MBs entering the localized region of the FUS beam undergo pressure-dependent oscillations and interact with tissue at time-averaged acoustic power levels that are over two orders of magnitude lower than the threshold without them [1, 2], and at more predictable pressures [3]. Compelling studies have highlighted the ability to elicit enhanced microvascular permeability [4, 5], inflammation [6], apoptosis [7], necrosis [8], thrombolysis [9, 10], thrombogenesis [11], angiogenesis [12], vessel rupture [13], and vascular shutdown [14, 15].

These effects are dependent on exposure conditions and have been linked to MB behaviors and
their interactions with vessels [16]. The most developed application of MB-mediated FUS is drug delivery, where pressures are typically limited to 100s of kPa and MB-induced microstreaming and mild endothelial cell deformation [4] gives rise to enhanced microvascular permeability and extravasation of circulating therapeutics. Importantly, these behaviors broadly correspond to emitted acoustic signatures, providing a means to enable non-invasive monitoring and facilitate treatment control [17, 18, 19] and clinical translation. These principles have been leveraged in clinical trials of drug delivery to the brain (with cavitation-based feedback control) [20, 21, 22, 19, 23], pancreatic tumors [24, 25], malignant neoplasms of the digestive system [26], and liver metastases from breast and colorectal cancers [27, 28].

Another approach for FUS MB-mediated therapy, focused on in this study, is to induce microvascular shutdown of blood flow and thereby tissue necrosis. This method has been referred to as mechanical ablation, nonthermal ablation, vascular disruption therapy or antivascular ultrasound (AVUS) [14, 15, 29, 30]. This approach is less studied than drug delivery and, as discussed below, effects typically occur at higher pressures (on the order of a few MPa, though tissue type, cavitation agent employed, and other pulse parameters are also determining factors) and may be linked to the presence of inertial cavitation [15, 31, 32]. AVUS has been demonstrated preclinically in a range of tissue types [33, 34, 32, 35, 36, 29, 37] and has potential for applications where tissue destruction is desirable, such as in selected brain regions or tumors, the latter being of interest in the present study. While AVUS has demonstrated tumor growth inhibition on its own, the most profound antitumor effects are elicited when combining with conventional approaches of chemotherapy [38, 15, 39, 40], antiangiogenic strategies [41, 42, 31], immunotherapy [43], and radiotherapy [44, 45, 46, 47, 48, 49].

When considered from a drug delivery perspective, the use of AVUS may at first appear counterintuitive in that disrupting microvessels would reduce drug access to the tumor. However, it has been proposed [15, 31, 39] that AVUS may act as a physical analog to small molecule vascular disruption agents (VDAs) [50, 51] which have a long history of being combined with conventional therapies – albeit with significant side effects [39, 15]. VDAs are known to preferentially shutdown blood flow and induce necrosis within the central regions of tumors, leaving behind a perfused rim and viable tumor cells [50, 52]. The differential spatial response of tumor microvessels to VDAs is attributed in large part to microvessels within the tumor center being smaller and less mature than those in the periphery, which have higher levels of stabilizing pericytes [50, 53, 54]. In addition to their endothelial cells being more susceptible to damage, immature microvessels are also rendered more permeable by VDAs, thereby elevating the already high interstitial fluid pressure in the tumour center, facilitating their preferential collapse [50]. This has led to a primary biological rationale for combining VDAs with chemotherapy; where VDAs treat the tumor center while the rim is addressed by chemotherapy (and other anticancer agents), which retains access to remnant tumor cells via the remaining tumor and proximal host microvessels [55]. A preferential perfusion shutdown in tumor centers has also been found to occur with AVUS in preclinical work [31, 15, 43, 40, 56]. With antiangiogenic strategies, the rationale is that antiangiogenic treatments block vascular rebound [57], which is consistent with results reported for AVUS with metronomic chemotherapy [31] and Sorafenib [42]. AVUS has also been combined with anti-PD-1 checkpoint blockade, where the combination treatments significantly inhibited tumor growth and enhanced survival relative to monotherapies and may be linked to initiating an adaptive immune response [43, 58]. Finally, there is a substantial body of work demonstrating that AVUS can profoundly enhance the antitumor effects of radiation therapy [44, 45, 46, 47, 48, 49, 59]. Here it is posited that MB stimulation mechanically perturbs endothelial cell membranes activating ceramide-based biomechanical pathways that enhance endothelial cell radiosensitivity, and radiation induces secondary cell death by ceramide-related endothelial cell apoptosis leading to vascular shutdown. The combination of AVUS and radiation therapy has been the first to emerge into clinical trials for head and neck cancer, and chest-wall and locally advanced breast cancer as of 2020 [60].

While the results to date suggest considerable potential for AVUS, relative to FUS MB-mediated drug delivery it is less well understood in terms of mechanisms, appropriate exposure conditions, and it lacks implementation of validated cavitation-based control methods. An overview of preclinical experiments studying AVUS in various tumor and tissue types is provided in Table S1. FUS exposures have utilized a range of frequencies (0.24 – 5 MHz), peak negative pressures from 0.18 – 10 MPa, modes of continuous wave and pulsed waves with a burst duration of 0.0015 – 100 ms, and pulse repetition frequencies (PRF) of 0.01 – 3 kHz; although within this parameter space only sparse exploration has been conducted. Exposure approaches have included continuous wave unfocused physiotherapy systems,
diagnostic ultrasound machines, and single-element fixed or scanned focused transducers for pulsed wave implementations. A variety of commercial and in-house MB types have been employed, with doses ranging from 1.5-3400x clinical diagnostic ultrasound dosing. It is possible that the range of parameters yield different mechanisms of vascular shutdown: For example, some studies indicate MB-induced endothelial damage followed by platelet aggregation and vessel thrombosis [61, 62, 36], while others report blood flow shutdown in the absence of hemorrhage or endothelial cell death [33, 63]. Similarly, studies have monitored vascular shutdown on different timescales, with immediate investigations of perfusion [58, 64, 65, 31, 15, 43] or later surrogate indications of endothelial apoptosis [66, 67, 44]. In addition, few studies have monitored cavitation during AVUS therapy [43, 15, 31, 68, 30] to formally link cavitation signatures to vascular shutdown.

Therefore, fundamental questions remain about the vessel sizes and types involved, timescale of effects, the nature of MB behaviors required to induce damage, and their associated acoustic signatures. In the present study we integrate ultrasound transmitters and receivers into a murine dorsal window chamber model for intravital microscopy studies capable of real-time visual and acoustic monitoring during and following FUS-induced MB cavitation. Vessel type (normal and tumor), caliber, and viability are assessed under therapeutic ultrasound conditions (1, 2, and 3 MPa to investigate pressure-dependence of effects), and cavitation signatures are linked to the biological effects. A 1 MHz transmit frequency millisecond scale pulsing regimen is employed, with a view towards the study information being compatible with array-based therapy systems currently under development. An improved mechanistic understanding of AVUS at the microscale is elucidated, with implications for establishing an AVUS-specific treatment protocol and control platform.

Materials and methods

Tumor cell line and animal preparation

This study utilized a squamous cell carcinoma (FaDu) cell line, which has been found to be well vascularized [69, 70, 71], is a good candidate for the setting of dorsal window chamber microscopy [72, 73], and has been previously employed to study vascular shutdown with vascular disrupting agents [74]. Green fluorescent protein tagged human FaDu squamous cell carcinoma cells (FaDu-GFP; Anti-Cancer Inc.) were cultured at 37 °C in a mixture of 5% CO2 and 95% air. Cells were propagated in RPMI medium 1640 with L-glutamine (MultiCell Technologies Inc.), supplemented with 10% FBS, 100 U/mL penicillin, and 100 µg/mL streptomycin, and were trypsinized and harvested prior to reaching confluence. Six to eight-week old BALB/c nude or athymic nude mice (Charles River Laboratories) underwent surgery for dorsal skinfold window chamber and tumor cell implantation (as in [69, 70, 71]): A titanium frame (APJ Trading Co. Inc.) was surgically implanted to hold the dorsal skinfold within a transparent window. The upper layer of the dorsal skinfold was removed, and then either 2x10⁶ FaDu-GFP tumor cells suspended in 30 µL of media (for mice with tumour-affected vasculature) or 30 µL of saline (for control mice with normal vasculature) were injected with a 30 G needle into the fascia in the center of the window. A 12 mm diameter glass coverslip was then placed over the exposed skinfold, and mice were monitored until imaging studies 7-9 days later. All animal procedures were approved and conducted in compliance with the Animal Care Committee guidelines at Sunnybrook Research Institute, Canada.

For imaging, mice were prepared as in [69, 70, 71] (Figure 1A-B). Briefly, mice were anesthetized with isoflurane with a 2:3 ratio of oxygen and medical air carrier gases. Tail veins were cannulated with a 27 G catheter, and mice were placed on a heating pad on a removable microscope stage with rectal thermistor feedback to maintain a core body temperature of 37 °C (TC-1000; CWE Inc.). The window chamber coverslip was removed, the skinfold was wet with degassed saline, and a 12 mm diameter, 150 µm thick glass coverslip with an in-house zirconate titanate PZT-4 ring transducer affixed to the top surface with cyanoacrylate adhesive was placed over the exposed skin and held with a retaining ring. The underside of the window chamber was coupled by ultrasound gel to a degassed water bath reservoir heated with a circulating water heater (T/Pump model TP-500; Gaymar Industries Inc.) to maintain the window chamber temperature at 37 °C. On the bottom of the water reservoir was an in-house polyvinylidene fluoride (PVDF) receive transducer used for passive cavitation detection. The removable microscope stage was then transferred to the multiphoton microscope for the study. It should be noted that tumours sometimes grew slightly off-centre within the window chamber, resulting in a range of locations (from center to towards the periphery of the tumour) being captured in the field-of-view (FOV). For inclusion in the study, mice with injected tumour cells were required to have both large patches of GFP-tagged tumour cells within the volume visualized, as well as noticeably affected (tortuous and redundant) vasculature.
Multiphoton microscopy settings

The dorsal window chamber was placed under a water immersion objective lens (25x 1.05 NA; XLPLN25xWMP2, Olympus) with a FOV of 500 µm x 500 µm. Laser scanning was performed using a multiphoton microscope (FV1000MPE; Olympus), exciting the sample at 900 nm with a mode-locked Titanium Sapphire tunable laser (690-1040 nm; MaiTai, Spectra-Physics). Fluorescent emissions following bandpass filtering were collected by a photomultiplier tube following bandpass filtering of 575-645 nm for tetramethylrhodamine (TMR dextran, 2 MDa; Invitrogen), and 495-540 nm for fluorescein isothiocyanate (FITC dextran, 2 MDa; Invitrogen) and FaDu-GFP cells.

Ultrasound parameters

In-house PZT-4 ring transducers were pressure calibrated with a fiber-optic hydrophone (Precision Acoustics) prior to experiments (Figure S1): The ring transducers (10 mm outer diameter, 8.5 mm inner diameter, 1.1 mm thickness) were affixed onto a 12 mm diameter, 150 µm thick glass coverslip with cyanoacrylate adhesive [75] (Figure 1C) and held in a window chamber by an internal retaining ring on the surface of a degassed, deionized water bath. A droplet of degassed, deionized water was placed in the inner part of the ring and coupled with an objective lens. A frequency sweep from 1-1.1 MHz in increments of 0.05 MHz was performed in thickness mode to achieve a minimum pressure change over 1-200 µm depth below the coverslip, corresponding to the maximum imaging depth (with a pressure change tolerance of < 15%). On average, the selected driving frequency was 1.05 ± 0.05 MHz, and the maximum peak negative pressure was at a depth of 50 µm below the coverslip, with a lateral full-width half-maximum (FWHM) at 50 µm depth of 0.6 mm, and axial FWHM of 1.55 mm.

For experiment sonication, the ring transducer was air-backed, with a droplet of degassed water in the inner part of the cylinder for compatibility with the water-immersion lens. Two arbitrary waveform generators (AFG3022B; Tektronix) were used to drive the ring transducer. One of these was used to control pulsing parameters, while the second one was used to trigger pulsing for a set number of repetitions: FUS exposures were performed at the ring transducer’s fundamental frequency with a pulse length of 5 ms, pulse repetition period of 10 s to enable inter-pulse reperfusion, for a 3 min duration at 1, 2, or 3 MPa peak negative pressure. The pressures employed are within range of previous AVUS studies (Table S1) and were refined based on pilot high-speed microscopy and cavitation monitoring of MB behaviour under longer, higher pressure pulses (such as those used for AVUS) in various channel sizes as a function of pressure [76]. These pulses were generated by the arbitrary waveform generators, attenuated by 20 dB (HAT-20+, DC-2GHz, MiniCircuits), amplified with a 55 dB RF power amplifier (model A150, 0.3-35MHz, 150 W, Electronics & Innovation), and transmitted through the ring transducer. Passive cavitation detection was performed with an in-house broadband PVDF receiver (4 mm diameter active element, Figure 1D) approximately 1.5 cm below the coverslip, centered at 10 MHz. Received signals were passed through a preamplifier and recorded for the entirety of the ultrasound pulses and were digitized at 125
MHZ with a 14-bit PC-based oscilloscope (PicoScope 6402C, Pico Technology Ltd.).

**Experimental procedure**

The objective lens and ring transducer were coaligned such that imaging captured the sonication focus in the center of the FOV. Following the procedure outlined in Figure 1E, TMR-dextran was first injected (6 mL/kg at a concentration of 5 mg/mL via tail vein catheter) to visualize the vasculature and adjust the multiphoton microscope excitation laser power and detector channel HV, gain and offset settings for imaging over depth. Imaging was completed from the surface of the dorsal skinfold to a depth of up to 250 µm to maintain a high signal-to-noise ratio for the microscope and remain close to the acoustic focus (for up to a 15% change in pressure). A baseline XYZ volume scan was acquired to create a 3D vascular map prior to treatment. Volume scans were acquired with 512 x 512 pixels (509.12 µm x 509.12 µm, resolution of 0.9944 µm/pixel) to a depth of up to 250 µm in 1 µm increments at 2 µs/pixel.

A tissue plane of depth between 30-75 µm was then selected such that vessels of various sizes could be visualized with good SNR and such that the FOV corresponded to approximately the maximum pressure. In the chosen plane, a baseline XYT time scan and baseline cavitation data were acquired with the same pulse sequence as would be utilized later for therapy. Single plane XYT time scans were acquired with the same lateral and temporal resolution as the volume scans, with a total imaging duration of 5 min to capture the duration of the bubble injection and sonication. Definity® MBs (Lantheus Medical Imaging Inc.) were then prepared as follows: MB vials were activated at room temperature in a VialMix (Lantheus Medical Imaging Inc.) for 45 s and then allowed to passively cool to room temperature. The MBs were then gently resuspended and allowed to decant for 30 s prior to extracting 50 µL for subsequent dilution in saline to a dosage of 60 µL/kg for injection through the tail vein catheter. This MB dose is equivalent to 3x the clinical imaging dose and is at the lower end of the range utilized in preclinical AVUS experiments (Table S1). Another time scan was then initiated at the same plane as the baseline scan, and ultrasound exposures were transmitted 10 s after MB injection.

At 5 min and 30 min post-sonication, volume scans were acquired to assess vascular damage and dye leakage. FITC-dextran was then injected (6 mL/kg at a concentration of 5 mg/mL via tail vein catheter) and volume scans were acquired to distinguish shutdown vessels at 35 min post-treatment and to assess potential recovery at 60 min post-treatment.

**Multiphoton microscopy data analysis**

**Spatiotemporal extravasation**

Multiphoton fluorescence images were first assessed in MATLAB (MathWorks) for dye extravasation. The 575-645 nm channel (corresponding to the TMR dextran) was corrected for GFP bleed-through, median filtered in 3-dimensions (3D), and contrast enhanced via contrast-limited adaptive histogram equalization. A binarized 3D vessel mask was then created through iterative thresholding to segment the intra- and extra-vascular compartments in the baseline XYZ volume stack (prior to MB injection and sonication). Average dye concentration changes in the intra- and extra-vascular compartments were then examined by applying the 3D mask to subsequent times (5, 30 min post-FUS), normalized to the compartmental volume and baseline fluorescence with the assumption that fluorescence is proportional to concentration. The area under the concentration-time curve (AUC) was then calculated by trapezoidal integration of the extravascular fluorescence as a function of time to yield a measure of bioavailability. Significance between pressure groups and compartments was evaluated with one-tail, two-sample, equal variance t-tests. Spatiotemporal release was then assessed as follows. A Euclidean distance transform of the segmented 3D vascular map was performed to create a distance map from each extravascular pixel to the nearest vascular structure, and applied to the extravascular compartment at baseline (0 min), and at 5 and 30 min post-FUS. Boundary effects were removed by truncating the volume by 20 pixels on all sides. Extravascular compartment fluorescence was normalized with respect to the compartment volume at each distance away from the nearest vessel, and to baseline fluorescence.

**Vessel measurements, events, and shutdown assessment**

Vessels were counted and sized in FIJI (ImageJ). Vessels were segmented by nodes such that any bifurcation divided the original vessel into multiple at the node. Each vessel was given a tracking identification and its diameter was measured by taking three measurements of the maximum length of the signal profile perpendicular to the local tangent along the length of the vessel and averaged. Vessels were tracked across multiple time points to assess changes upon sonication: Vascular deformation was identified when the path of a vessel underwent a localized displacement. It should be noted that the dorsal skinfold model employed here is well
supported with a chamber frame and from below such that tissue motion that not associated with the ultrasound exposures was effectively eliminated. Vasoconstriction and vasodilatation were noted when vessel diameter constricted or dilated by at least 10%. Flow reversal was classified by tracking a reversal in the bulk motion of the fluorescent dextran or dark voids of red blood cells through vessels. Vascular occlusions or clots were identified when red blood cells were observed to form large clots that moved slowly or became trapped in vessels. Focal disruption or leakage was classified upon visualization of distinct fluorescent dextran extravasation, visualized first during the sonication in the XYT time scan or in the 5 min XYZ volume scan, and becoming more diffuse over subsequent imaging timepoints. Following sonication, the images upon FITC-dextran injection (35, 60 min post-FUS) were utilized to assess whether vascular shutdown occurred. Injection of this second dye was necessary to enable clearer visualization of shutdown, as diffuse TMR dye from leakage events as well as slower flow in some vessels frequently precluded the reliable assessment of shutdown with one dye alone. Vessels were classified as viable if the FITC-dextran flowed through them (i.e. they appeared yellow or green) and shutdown if they remained red or appeared dark at 35 min. Shutdown was then categorized as transient if the vessel blood flow recovered, or sustained if the vessel remained red or dark at 60 min. Vascular events were normalized to the total number of vessels visualized at each pressure. Significance was calculated with a one-way analysis of variance (ANOVA) and a multiple comparison test in MATLAB.

Cavitation data analysis

Acoustic data was post-processed in MATLAB (MathWorks). Received signals (baseline acquired prior to agent injection, and bubble cavitation acquired upon MB injection and sonication) were digitally filtered by a 5th order bandpass Butterworth filter (0.3 MHz high-pass and 10 MHz low-pass) and were then processed in two different ways. The first method assessed the entire received signal burst-by-burst by multiplying by a 5 ms rectangular window centered on the received signal. The second method assessed the cavitation response over time throughout the first burst by multiplying by a moving 100 µs Hanning window. The moving window began at the beginning of the received signal and moved by 50 µs increments (50% overlap) to reach the end of the 5 ms received signal. For both methods, windowed received signals were zero-padded to a frequency resolution of 200 Hz per division prior to computing the Fourier transform. Example spectra are composed of the averaged power spectra of the first two bursts within the first millisecond window for both baseline and bubble cavitation signals, both normalized to the mean power between 3.1 and 3.4 times the fundamental frequency of the first burst in the baseline signal for each mouse. Quantified cavitation data was calculated by integrating the power spectra (obtained with the 5 ms window on the first burst) over the following frequency bands of interest; inertial cavitation IC (mean over (1.9-1.95)f1 and (2.05-2.1)f1), subharmonic 1/2f1 (mean of 4 kHz bandwidth around the peak point value), 1/3+2/3 subharmonic (mean of 4 kHz bandwidth around (1/3)f1 and (2/3)f1), relative subharmonic (subtraction of the surrounding broadband mean power at (0.43-0.46)f1 and (0.54-0.57)f1 from the subharmonic), ultraharmonic 3/2f1 (mean of 4 kHz bandwidth around the peak value), 1/3+2/3 ultraharmonic (mean of 4 kHz bandwidth around (4/3)f1 and (5/3)f1), and the relative ultraharmonic (subtraction of the surrounding broadband mean power at (1.43-1.46)f1 and (1.54-1.57)f1 from the ultraharmonic). As discussed later, the use of these specific third-order sub- and ultra-harmonic frequencies is atypical and is based on the spectral observations that emerged. Quantified cavitation data involves the subtraction of baseline signals from bubble cavitation signals, except for the ‘relative’ bands. Statistical significance on quantified cavitation data above was calculated by performing right-tail one-sided t-tests, with the null hypothesis being that the subtraction of the integrated baseline data from the bubble data would equal zero. Quantified cavitation data was further provided as a function of burst number (with the first assessment method above of burst-by-burst 5 ms rectangular windowing), and within the first burst (with the second method above using a moving 100 µs Hanning window) to indicate persistence. Inertial cavitation dose was calculated by summing the quantified cavitation data in this band across all 18 bursts of the treatment duration for each mouse (for the bubble cavitation data). The average and standard deviation of the inertial cavitation dose was then calculated for each pressure group. Statistical significance between pressure groups was calculated by performing one-tail, two-sample, equal variance t-tests on the integrated power between the pressure groups.

Results

Effects induced during therapeutic ultrasound exposure

A range of vascular events were visualized upon ultrasound exposure of injected MBs (1.05 MHz, 5 ms
pulse length, 10 s pulse repetition period, 3 min duration at 1, 2, or 3 MPa peak negative pressure) during XYT time scans as well as immediately following sonication through XYZ volume scans at 5 min, depicted in Figure 2. Video examples of events occurring during XYT time scans can be found in the Supplementary Information. Events were typically more prominent as a function of increasing pressure (Figure 2A).

Rapid-onset events captured within the first 30 s of sonication during the X YT time scans included vascular deformation, vasoconstriction, and vasodilation (Figure 2B-D), each of which involved smaller vessels with greater severity. In many cases where sudden (between frame) focal disruption occurred, this was accompanied by substantial and diffuse tissue motion, where tissue typically did not fully relax to its prior state for a number of frames. Such motion was also evident for events that appeared to occur outside of the optical focal plane (See Videos S1-8). Frequently following these events, focal disruptions resulting in localized dye leakage could be observed, typically occurring within the first minute of sonication near bifurcations (Figure 2E). Formation of clots or occlusions could be visualized close to points of focal disruption later during sonication but was not a common occurrence (Figure 2F). Throughout the exposure duration though, flow directionality reversal could be observed (Figure 2G), sometimes preceding focal disruptions (though with the limitation that only a single plane could be visualized at this temporal resolution during sonication) and often following them. Flow reversals occurred not only in the vessels experiencing focal disruptions but in up- and down-stream connected vessels in the network. Vessels experiencing focal disruptions were also prone to exhibiting blood flow shutdown (Figure 2H). This event could be observed towards the end of sonication with vessels appearing dark or with stagnant erythrocytes, and could be more easily identified with the addition of a second dye (FITC dextran) at 30 min following sonication. Notably, many vessels up- and down-stream in the network from a focal disruption experienced flow reversal followed by flow shutdown, though sustained events of shutdown (60 min) were more likely to be close to the original disruption location. The most prominent events of focal disruption and shutdown will be further analyzed in the following section.

Figure 2. Microvascular events induced by vascular disruption therapy visualized with intravital multiphoton microscopy. Fluorescent FaDu-GFP tumor cells are visualized in green, injected 2 MDa TMR-dextran is red, and injected 2 MDa FITC-dextran is yellow. The scale bars represent 100 µm. White arrows indicate the events. (A) Relative occurrences of various vascular events visualized at 1, 2 and 3 MPa. Events are normalized to the total number of vessels visualized at each pressure. * p < 0.05, ** p < 0.01, *** p < 0.001. (B) Vascular deformation.
deformation seen as twisting and displacement of vessels in the first 15 s of sonication (XYT time scan). (C) Constriction and (D) dilation of vessels, often seen within the first 30 s of sonication (XYT time scan). Throughout the duration of sonication vascular disruptions were observed including focal and more diffuse leakage, frequently following the above-mentioned events (or preceding, in the case of vascular shutdown) when they occurred (typically within the first 1 min of sonication; XYT time scan). (F) Formation of clots occluding a vessel, occurring slowly and towards the end of sonication (XYT time scan). (G) Red blood cells visualized flowing towards and then away from a node in an apparent flow reversal (XYT time scan). (H) Vascular blood flow was observed to stop for at least 35 min after sonication, and in some cases recover by 60 min (visualized through XYZ volume scans at 0, 35, and 60 min following sonication).

Figure 3. Spatiotemporal extravasation, bioavailability, and enhanced vascular permeability and shutdown following ultrasound exposure as a function of pressure. (A) Mean extravasation distance surface plots from the nearest vessel as a function of time in tumor-bearing mice treated at 1 (n = 7), 2 (n = 9) and 3 (n = 7) MPa from XYZ volumetric scans at t = 0, 5, and 30 min. (B) Area under the curve (AUC) measurements (mean and standard deviation), demonstrating increasing extravascular bioavailability of injected TMR-dextran (as a drug surrogate) after ultrasound exposure. * p < 0.05, ** p < 0.01, *** p < 0.001, n.s. = not significant. (C) Histograms of absolute counts of all visualized vessels overlayed by vessels exhibiting leakiness as well as both leakiness and flow shutdown at 1, 2, and 3 MPa in mice with tumors. Histograms of percentage of leaky as well as leaky and shutdown vessels normalized to total visualized vessels at 1, 2, and 3 MPa are inset. (D) Summary of shutdown and leakage occurrences, as well as the overlap of these events in small (< 20 µm) and large (> 20 µm) diameter vessels. Percentages are provided normalized to the total number of vessels studied at each pressure.

Vascular leakage and blood flow shutdown following antivascular ultrasound

The most prominent vascular event to occur during ultrasound exposure was focal disruption, also referred to here as leakage, with frequent occurrences of subsequent shutdown. Leakage was first visualized as being focal during sonication throughout the XYT time scan, consistent with association with a local bubble event. It was then found to plateau and become more diffuse through subsequent XYZ volume scans at 5 and then 30 min following sonication. Focal disruption events were found to exhibit increasing extravasation distance and quantity with rising pressure (Figure 3A-B). Of note is the fact that vessels experiencing focal disruptions also frequently exhibited blood flow shutdown (Figure 3C), evident at 35 min following sonication. Specifically, of the total vessels that experienced leakage, 16% also exhibited shutdown at 1 MPa; 37% at 2 MPa; and 79% at 3 MPa. Both leakage and shutdown preferentially occurred in smaller vessels (< 20 µm diameter), and progressively affected larger and more vessels with increasing pressure (Figure 3C-D). It is also notable that with increasing pressure, up- and down-stream vessels networked with the focally disrupted vessel progressively also sustained flow shutdown (resulting in a marginal increase in total leakage events, but a substantial increase in shutdown vessels: Of the vessels experiencing shutdown, 22% also had a leakage event at 1 MPa; 70% at 2 MPa; 52% at 3 MPa). It was also observed that not all vessels with leakage events also exhibited shutdown and vice versa, but there was substantial overlap with increasing pressure (Figure 3D, Figure S2). The mean vessel sizes shutdown (with or without leakage) were also similar to those with leakage and indeed the overall examined vessel mean (Table S2).

Figure 4A displays histograms of vessels with flow shutdown induced by ultrasound, overlayed with a subset of vessels that recovered flow within 1 h after treatment. Shutdown occurred preferentially in
smaller vessels, affecting larger and more vessels with increasing pressure (the largest being 71 µm diameter). Recovery occurred preferentially at lower pressures and in smaller vessels (Table S3). For comparison, normal mice (sham surgeries) were utilized as controls. The same trends applied to the normal mice, but with overall lower incidence suggesting a self-targeting effect to tumors. Consideration of all vessels (i.e. without binning) demonstrates further the propensity of vascular shutdown in tumors compared to normal tissue, as well as the tendency of shutdown vessels to recover at lower pressures and preferentially in normal tissue (Figure 4B-C, Table S3, Figure S3).

Figure 4. Blood flow shutdown induced by ultrasound in tumor-bearing and normal mice. **(A)** Histograms of absolute counts of all visualized vessels overlayed by vessels exhibiting shutdown and recovery at 1, 2, and 3 MPa in tumor-bearing and normal mice. Histograms of percentage of shutdown vessels overlayed with recovered vessels normalized to total visualized vessels at 1, 2, and 3 MPa are inset. **(B)** Total percentage shutdown in tumor and normal tissue at 1, 2, and 3 MPa. Stacked colours indicate the relative breakdown of shutdown vessels that recover (black in tumors, grey in normal tissue) and exhibit sustained shutdown (red in tumors, yellow in normal tissue). For tumor tissue, increasing pressure results in significant increases in vascular shutdown, whereas in normal tissue significance is not reached until 3 MPa. P < 0.05 = *, p < 0.01 = **, p < 0.001 = ***. **(C)** Summary of total number of subjects and vessels studied, along with relative percentages of vessels exhibiting shutdown. Of the shutdown vessels, relative percentages of recovered and sustained shutdown vessels are provided.

Figure 5. Sample cavitation spectra ultrasound exposure. The fundamental frequency ($f_1$) and second harmonic (2$f_1$) are present at 1, 2, and 3 MPa. As pressure increases, broadband noise as well as distinct sub- and ultra-harmonics emerge, along with sharp peaks at 1/3 and 2/3 of the sub- and ultra-harmonics.
Cavitation signatures linked to antivascular ultrasound

Acoustic emissions were monitored during treatment to link cavitation signatures to vascular shutdown (Figure 5). At 1 MPa, peaks at the fundamental and second harmonic were detected along with a degree of inertial cavitation. At 2 MPa, sub-and ultra-harmonic peaks began to emerge along with peaks at 1/3 and 2/3 of the sub- and ultra-harmonics respectively and broadband noise. At 3 MPa, sub- and ultra-harmonic peaks as well as their 1/3 and 2/3 peak counterparts became more distinctive above the broadband noise. Notably, the microscopy data indicated a higher degree of vascular shutdown with elevated pressure, signifying the possibility of utilizing broadband noise as well as the sub- and ultra-harmonics (and their 1/3, 2/3 elevated counterparts) as indicators for antivascular ultrasound therapy.

Quantifying cavitation data in specific frequency bands across mice and pressure groups in tumor vasculature (Figure 6), it was found that harmonic peaks (subharmonic, ultraharmonic, relative sub- and ultra-harmonics, and relative 1/3, 2/3 sub- and ultra-harmonics, broadband noise indicative of inertial cavitation) become elevated with increasing pressure. Specifically, power in these peaks became statistically significant at 3 MPa. As a metric of IC dose, the integrated IC metric over all the bursts is shown in Figure 6C, showing that there is a significant difference in dose at 3 MPa. IC dose was also found to significantly increase from 1-3 and 2-3 MPa.

In normal tissue, however, fewer frequency bands of interest reached statistical significance (Figure S4). At 1 MPa, power in the relative 1/3 and 2/3 subharmonic was significant. At 2 MPa, power in the 4/3 and 5/3 ultraharmonic bands became significant. At 3 MPa, only power in the 1/3 and 2/3 subharmonic and the relative 1/3 and 2/3 subharmonic peaks was significant.

Cavitation signal persistence was variable across treatment duration in both tumor-affected and normal tissue (Figure S5). Power in the frequency bands of interest generally decayed quickly over the first 3 bursts, then either continued to decay slowly (subharmonics) or remained plateaued (inertial cavitation, ultraharmonics) for the duration of the 18 burst treatment. Within the first burst, inertial cavitation was found to begin elevated and decline rapidly within the first ~100 µs of the 5 ms pulse length. The other harmonic peaks displayed variable behavior over the pulse length. In general, the subharmonics were found to increase over the first 1 ms of the pulse length, then decay, then again rise later (at ~3 ms) and fall again. The ultraharmonics were also found to generally rise over the first 1 ms and then fall, with only the third order ultraharmonics rising again closer to the end of the pulse length, at 4 ms.

![Figure 6](https://www.thno.org)

**Figure 6. Cavitation data summary.** (A) Box and whisker plots displaying the integrated power (of treatment with baseline subtracted) for each pressure group at various frequency peaks for the first burst in tumor tissue. The red crosshairs indicate outliers. (B) Table of the p-values for t-tests of the linear power subtraction of baseline from bubble data at each frequency peak of interest. Groups with statistically significant (p < 0.05) elevation above baseline are highlighted in yellow. (C) IC dose (ICD) as a function of pressure. *p < 0.05, n.s. = not significant.
Discussion

A growing body of preclinical work suggests that AVUS has considerable potential to enhance the antitumor effects of conventional methods of chemotherapy [38, 15, 31, 39, 40], antiangiogenic strategies [41, 42, 39], immunotherapy [43, 58], and radiotherapy [44, 45, 46, 47, 48, 49]. Initial clinical trials are underway investigating AVUS-mediated radiosensitization ([77], NCT04431674, NCT04431648), albeit using systems that were not developed for cavitation-based FUS. As is the case for cavitation-based FUS drug delivery, to fully harness the potential of AVUS it is necessary to gain an understanding of the impact of the biological effects induced under different exposure conditions and their link with cavitation signatures. The present study was performed to elucidate FUS effects at the microvascular level in real-time in an acute setting, with the goal of providing information that informs the rational development of exposure and control systems for AVUS.

The most prominent immediate events observed during sonications (via XYT time acquisitions) were focal microvascular disruptions as indicated by localized dye leakage, which increased in prevalence with pressure and became more spatially diffuse over time. In addition to permeabilization effects, MBs can promote the extravasation and transport within the extravascular compartment via microstreaming. This has been shown to be pronounced in the presence of inertial cavitation [78], and is hypothesized to be a factor in promoting the delivery of biologics to tumors [79]. The dye used in this study was 2 MDa dextran. This is considerably larger than typical biologics mimicked by dextrans of 40-70 kDa that exhibit higher accumulation in solid tumors due to their lower hydrodynamic radius permitting diffusive transport, while 2 MDa dextran has little to no passive uptake [72]. This implies that AVUS regimes can also enhance drug delivery, to a greater degree with more conventional sized biologics than exhibited here. The extravasation of dye or nanoparticles from microvessels during FUS has been previously observed with intravital microscopy in both normal [80, 61, 81] and tumor [62, 40, 65, 70] tissue. These events accrued during the course of successive pulses following MB injection, with subsets resulting in flow cessation in the same vessel within seconds. Apparent ‘vascular disruption’ or rupture has been previously observed (Table S1), though few studies provide insight into possible flow cessation associated with these events. Although leakage from the first dye injection enabled insight into focal disruptions, its diffusion over time did not permit reliable quantification of sustained vascular shutdown, which was enabled by the volumetric analysis of the second dye distribution. Collectively these data indicated that only a subset of observed focal events were sufficiently strong to induce sustained vascular damage, with the remainder only resulting in enhanced permeabilization and transport of dye to the extravascular space. The proportion of focal events associated with vascular shutdown increased with pressure (79% at 3 MPa), and the variability of effects is nominally consistent with the polydisperse nature of Definity and the expected influence of vessel size on MB response. Conversely, only a fraction of vessels that were observed to have no flow (shutdown) also had a focal event within them (52% at 3 MPa). If it is assumed that a MB event that is sufficiently strong to induce vascular shutdown of the vessel would also produce dye leakage (to be classified as a focal disruption event), then this suggests that the flow cessation is not due to an event occurring within the vessel. Indeed it should be noted that 52% is an upper bound of the number of vessels that are shutdown due to a focal event within them, as it is possible that the focal disruption event within them may have simply been a permeabilization event.

Collectively considering all vessels, there was a progressive increase in vascular shutdown in tumors with pressure, being significantly higher at 3 MPa than 1 and 2 MPa (Figure 4B). It was also found that smaller vessels were preferentially affected: vessels experiencing shutdown were strictly below 20 µm in diameter at 1 MPa, while at 3 MPa more vessels of larger diameters (up to 71 µm) were affected (Figure 3C-D). The sensitivity of smaller vessels to FUS has also been investigated previously. Prior theoretical and experimental studies have suggested that with increasing pressure, particularly in smaller vessels, MB oscillations become increasingly violent – resulting in rapidly increasing vessel wall displacements inducing substantial intraluminal pressure on the wall [82]. Additionally, damped oscillation amplitudes of MBs in smaller vessels results in reduced instability and increased oscillation lifetime, causing MBs to interact longer with the vessel wall [83]. These factors result in a greater chance of wall disruption that rapidly increases with pressure. It is also useful to

https://www.thno.org
consider the results in the context of what is known about the action of VDAs: As with VDAs, AVUS most readily initiates damage in the smallest microvessels [50, 84]. VDAs also preferentially impact immature microvessels that lack pericytes, which has not been assessed here but warrants future investigation. The high levels of dye leakage following treatments with AVUS is consistent with increased microvascular permeability, which also occurs with VDAs and is thought to be a contributing factor to its ability to reduce perfusion as a result of its impact on interstitial fluid pressure.

There is considerable microscopy-based evidence in normal vascular beds of localized microvascular damage \textit{in vivo} due to FUS, in particular with demonstrations of capillary rupture (\textit{Table S1}, [85,86, 61, 83, 87]). In many circumstances, this work was carried out with a view to assessing potential bioeffects of MBs for conditions relevant to diagnostic MB contrast imaging with short imaging pulses. To date there is little direct quantitative evidence of flow cessation as a function of microvessel sizes, in normal or tumor tissue, under conditions that may be relevant to assessing AVUS therapy. In [51] the use of single short (3 cycle) pulses for acute vascular damage was assessed and observed that smaller vessels were preferentially affected and that the size increased with pressure (3-7 MPa). Notably in [51], at 3 MPa (our maximum and their minimum pressure) there were far fewer and smaller vessels shutdown than in the present study. While a direct comparison is confounded to an extent by differences in methodology, a likely factor in accounting for our increased level of vascular shutdown at lower pressures is the use of longer pulses, which were done here for compatibility with narrowband therapy array systems.

Vascular shutdown was found to occur more frequently in tumor-affected vessels, with greater severity as a function of increasing pressure. At 1 MPa, 38.5% of vessels exhibited sustained shutdown in tumors compared to 0% in normal tissue; while at 3 MPa, 97.1% of affected tumor vessels experienced sustained shutdown compared to 75.7% in normal vasculature. This preferential impact on tumor microvessels is also consistent with previous data for VDAs, which has been attributed in large part to them being immature (with fewer stabilizing pericytes) and the possible effects of elevated interstitial fluid pressures. This propensity to affect tumor microvessels rather than normal tissue has fortuitous implications for reducing off-target effects for therapy which is necessary to consider from a safety perspective as this new treatment approach transitions to clinical evaluation. For example, information about the damage threshold for normal tissue can be used to inform the focal characteristics of the beam such that pre-focal normal tissue present in the path length between the transducer is not damaged. Necessarily, the damage threshold in the relevant tissue type must be assessed, as it can be expected to vary (for example, the vulnerability of brain tissue as indicated by the varying parameters used, outlined in \textit{Table S1}).

This study used FUS exposures at \~1 MHz, with a pulse length of 5 ms, and pulse repetition period of 10 s for a 3 min duration, at 1, 2, or 3 MPa. These parameters fall in the range of protocols used in other AVUS studies that have been carried out in bulk tumor or normal tissue (frequency 0.24-5 MHz; modes of continuous or pulsed waves of 0.1-100 ms with pulse repetition frequencies of 1-10 kHz; peak negative pressures of 0.18-5 MPa; \textit{Table S1}). A direct comparison of the results obtained here with previous work is complicated by factors such as MB dose, FUS pressures, and the metrics and timepoints of assessing antivascular effects. In terms of dosing, the levels used here are higher than those employed clinically in a diagnostic ultrasound setting but are within range of what is being utilized in initial clinical trials and in our prior preclinical work. Notably in our previous studies [43, 15, 31], a peak negative pressure on the order of 1.6 MPa was applied to induce vascular shutdown, though due to the use of a loosely focused transducer to enable complete coverage of subcutaneous tumors (f-number 4) non-linear propagation resulted in peak-positive pressures on the order of 3.5 MPa. Antivascular effects have been reported in preclinical tumors at lower pressures but with substantially higher MB doses (\textit{Table S1}). It is also notable that our metric here is sustained vascular shutdown at the 1 h point, whereas many other studies assess vascular shutdown and tissue death (necrosis, apoptosis) at longer timescales (24 h). However, it has been shown that vascular shutdown immediately following treatment of tumor tissue has been associated with subsequent tissue necrosis [31, 35].

This study also permitted a comparison of observed microvascular effects with cavitation data derived from the microvascular bed. As a general point, at higher pressures inertial cavitation was observed alongside distinct peaks at subharmonic and ultraharmonic frequencies. The latter included not only the widely reported order 1/2 subharmonic and 3/2 ultraharmonic but also more complex order 1/3, 2/3, 4/3 and 5/3 harmonics. These can in principle arise from spherically symmetric bubble oscillations [88] and have also been reported in the context of laser induced bubble clouds [89]. In a FUS setting, these have previously been observed anecdotally in the
spectra in subcutaneous mouse tumors [31], and recent evidence from a phantom study suggests that they only arise from bubbles in microvessels less than 50 µm in diameter at higher pressures (2 and 3 MPa) [76]. Inertial cavitation was found to increase significantly as a function of pressure and this was accompanied by increases in vascular shutdown. Previous work in mm-sized vessels has linked vascular damage with inertial cavitation [11]. This is also consistent with a wide range of studies that link the in vivo presence of inertial cavitation (detected in larger volume samples and focal regions) with vascular bioeffects such as erythrocyte extravasation. Recently in [30], inertial cavitation levels were linked to subsequent non-thermal necrosis regions induced by vascular shutdown. In [40] microvascular damage as measured by microscopy was linked to inertial cavitation as measured in a phantom under similar conditions. Aside from inertial cavitation, we have shown significantly elevated levels of a variety of sub- and ultra-harmonics, alone or in combinations, at increasing pressure levels. Notably, this is also the case for the ‘relative’ peaks, which are measured relative to the inertial cavitation level to draw conclusions about the peaks. It also warrants comment that the lack of significance of the inertial cavitation, subharmonics and ultraharmonics relative to the baseline until 3 MPa appears to depart from previous FUS drug delivery and MB characterization studies in terms of the pressure onset, which may be due to several factors. One is that the expected signal strength in this study is lower due to the smaller volume of tumor present in the beam compared to a situation of the entire therapy focus being filled with tumor tissue. A second is that we are examining a microvascular bed (no contributions from larger vessels as is the case with larger tissue volumes) and microvessels are expected to have a higher pressure threshold for the onset of inertial cavitation [90] and sub- and ultra-harmonics [76]. The onset of significance of the different order (1/3 and 2/3) subharmonics and (4/3 and 5/3) ultraharmonics at a pressure level that corresponds to high levels of vascular disruption suggest that their use for control and dose monitoring warrants investigation.

The current study also indicated a high level of variability in terms of cavitation signal persistence: At 2 MPa with just under 25% shutdown, inertial cavitation only persisted for ~0.1 ms and for 1-2 bursts, while sub- and ultra-harmonic peaks (and their associated 1/3, 2/3 peaks, when they occurred) generally persisted over the full 5 ms pulse length, but were short-lived for only 1-2 bursts of the 18 burst (3 min) total duration. At 3 MPa, inertial cavitation again persisted for ~0.1 ms during bursts but persisted (with some decay) across the full 18 burst treatment duration. Other harmonic peaks again persisted over the full 5 ms pulse length, for variable repeated bursts ranging from 2-18 of the total 18 burst duration. This indicates that while 5 ms pulse lengths are sufficient for vascular shutdown, shorter pulse lengths of 0.1 ms are worth exploring. It additionally indicates that a 3 min total treatment duration is not strictly necessary to achieve vascular shutdown, and shorter treatment timelines may suffice. The recorded cavitation signal patterns noted here may aid in establishing a more specific AVUS treatment protocol, and further indicate a potential basis for acoustic feedback control to monitor and maximize treatment efficacy.

The observed vessel events and their time-course following AVUS shed some light on underlying vascular disruption mechanisms. As noted above, an insight provided here is that vascular shutdown appears due to a combination of vessels that have had a bubble event occur within them that induces shutdown, as well as vessels where flow has ceased due to shutdown elsewhere in the network. The following discussion relates to the former case. One proposed model in the literature is that AVUS damages the endothelium, inducing platelet aggregation and vessel thrombosis [62, 33], which is derived from data using endothelial cell targeted MBs and shorter pulses at higher pressure. However, clot formation and vascular occlusions were rarely visualized here, occurring only 6.8% of the time at 3 MPa. This may be due to different exposure conditions (shorter, higher pressure pulses were employed in [32]) or due to the use of endothelial cell targeted MBs in [32]. Thrombus, alongside endothelial cell damage was also observed in [11], although this was in mm-sized vessels. This study also visualized numerous cases where blood flow shutdown was transient with no obvious structural changes, pointing perhaps to mechanisms of vascular deformation or vasoconstriction. These effects too, however, were only visualized in up to ~5% of vessels at higher pressures. Another proposed model in the case of combined AVUS and radiotherapy is that endothelial perturbation can upregulate ASMase and ceramide [48, 66], leading to endothelial cell death. Our results do not exclude that this is happening, though it should be noted that the timescale of shutdown in the present study (seconds) is far shorter than the timescale of apoptosis induction and as such this is unlikely to be the cause of shutdown here. As the radiosensitization work was conducted at lower pressures (500-750 kPa) and with higher MB doses, it is reasonable to consider that different mechanisms can be responsible for vascular disruption, depending on the exposure conditions. Indeed the XYT data
indicate that events that give rise to vessel shutdown are localized and involve the ejection of dye into the extravascular space which is consistent with previous reports of rupture in capillaries [85, 86, 61, 87] and in tumor vessels [40]. In [85] evidence was provided of endothelial cell injury near rupture sites that had erythrocyte extravasation. Ex vivo experiments with high-speed camera measurements also suggest that capillary walls and endothelial cells can be damaged with violent bubble oscillations [83, 91].

The XYT data also demonstrate that focal disruption is frequently accompanied by substantial localized tissue and microvessel deformation. While the frame rate (1.086s) is orders of magnitude too low to visualize deformations occurring at the timescale of bubble oscillation, it is evident that this motion and deformation extends into and well beyond the perivascular space and can take a number of image frames to recover to its original position. The precise origins of these deformations have yet to be established, but the localized characteristics are consistent with them being associated with bubble oscillations (including transient events - e.g. collapse, jets) and/or Bjerknes radiation forces. The implications of this degree and type of motion and strain on vascular effects and possible fluid transport [92] warrant investigation. Finally, as AVUS has been shown to be particularly effective when combined with other therapeutic agents [38, 15, 31, 43, 66]; the enhanced extravasation effects into the tumor extravascular space and greater bioavailability promoted by FUS at higher pressures may facilitate such synergistic outcomes.

Study limitations should be noted: while studies were conducted over the same timeframes, tumor growth varied across mice in terms of tumor size, vessel involvement, and location within the dorsal window. As imaging and sonication were physically constrained over a region of interest in the center of the window chamber, such differences in tumor size and location may have affected the morphology and strength of the visualized vessels. The vessel size distributions were also heterogeneous, making interpretation of cavitation results and their correlation with vascular events difficult. It should further be noted that a single cell line (FaDu) and superficial model (dorsal window chamber) were utilized in this study. Vascular metrics of the FaDu cell line have been assessed previously [72, 73], and it has been previously employed in the study of vascular shutdown with vascular disrupting agents [74]. Further, while studies comparing tumor cell lines have yielded some qualitative differences, few quantitative differences in vascular metrics have been observed [93]. It should also be noted that the use of intravital microscopy in the superficial dorsal window chamber tumor has been used previously as an important tool to provide insights into vascular effects [84, 93, 74]. It is also noteworthy that pilot experiments determined that 3 MPa sonications in the absence of MBs were capable of inducing a small degree of vascular disruption, presumably due to endogenous cavitation seeds. For this reason, baseline sonications were limited to a shorter duration of 2-3 bursts, which did not result in notable disruption. It should also be noted that several ring transducers were fabricated to expedite experiments due to their fragile nature; while these were each calibrated prior to experiments, minor pressure distribution differences existed between different rings which may have contributed to variability within pressure groups. Finally, a single-element receiver coaxially aligned with the therapy beam was employed here, and cavitation signals were therefore associated MBs interacting with a number of vessels of different calibers. A future configuration with an array-based receiver and super-resolution approaches is of interest to spatially map cavitation within the tumour, as well as to assess cavitation within individual microvessels [76, 94].

Conclusion

AVUS has experienced early preclinical success however, the establishment of standard protocols and control approaches has been impeded by fundamental questions about exposures, vessel types and sizes involved, and the nature of acoustic cavitation resulting in vascular damage. Here, vessel type (normal and tumor-affected), caliber, events, and viability were assessed during ultrasound exposure (1, 2, and 3 MPa) of circulating exogenous MBs, and associated cavitation was monitored. Vascular events were found to occur with greater incidence in smaller vessels, with more severity as a function of increasing pressure, and with higher incidence in tumor-affected vessels. Vascular shutdown was observed to be due to a combination of focal disruption events and network related flow inhibition. Detected acoustic emissions indicated elevated broadband emissions along with sub- and ultra-harmonics and their associated 1/3 and 2/3 peaks with increasing pressure. Identification of broadband emissions and distinct sub- and ultra-harmonics taken collectively with identified vascular events provide an improved mechanistic understanding of AVUS at the microscale, with implications of establishing a specific treatment protocol and control platform.
Supplementary Material

Supplementary figures and tables. https://www.thno.org/v13p0250s1.pdf
Supplementary video 1. https://www.thno.org/v13p0250s2.avi
Supplementary video 2. https://www.thno.org/v13p0250s3.avi
Supplementary video 3. https://www.thno.org/v13p0250s4.avi
Supplementary video 4. https://www.thno.org/v13p0250s5.avi
Supplementary video 5. https://www.thno.org/v13p0250s6.avi
Supplementary video 6. https://www.thno.org/v13p0250s7.avi
Supplementary video 7. https://www.thno.org/v13p0250s8.avi
Supplementary video 8. https://www.thno.org/v13p0250s9.avi

Acknowledgements

The authors thank S. Bulner for performing tumor cell culture; V. Chan and S. Rideout-Gros for advising on the dorsal skinfold window chamber implantation surgeries; M. A. O’Reilly for designing the PVDF receive transducer; A. Wright for constructing the ring PZT transducers and PVDF receive transducers; M. A. Santos for pilot study guidance; and A. Dorr for her support in using the multiphoton microscope. Funding was provided by the Canadian Institutes of Health Research (PJT 156131), Ontario Research Fund, and the Provost’s PhD Engagement Fund Sunnybrook Award.

Competing Interests

The authors have declared that no competing interest exists.

References

1. Hynynen K, McDannold N, Vykhodtseva N and Jolesz FA. Noninvasive MR imaging-guided focal opening of the blood-brain barrier in rabbits. Radiology. 2001; 220(3): 640-646.
2. Tran BC, See J, Hall TL, Fowlkes JB and Cain CA. Microbubble-enhanced cavitation for noninvasive ultrasound surgery. IEEE TUFFC. 2003; 50(10): 1296-1304.
3. McDannold N, Vykhodtseva N and Hynynen K. Targeted disruption of the blood-brain barrier with focused ultrasound: Association with cavitation activity. Phys Med Biol. 2006; 51(4): 793.
4. Kootman K, Vos HJ, Versluis M and de Jong N. Acoustic behaviour of microbubbles and implications for drug delivery. Adv Drug Del Rev. 2014; 72: 28-48.
5. Deckers R and Moonen CTW. Ultrasound triggered, image guided, local drug delivery. J Control Rel. 2010; 148: 25-33.
6. Miller DX, Dou CV and Armstrong WE. The influence of agent delivery mode on cardiomyocyte injury induced by myocardial contrast echocardiography in rats. Ultrasound Med Biol. 2005; 31: 1257-1263.
7. Vykhodtseva N, McDannold N, Martin H, Bronson RT and Hynynen K. Antitumor effects of ultrasound-produced threshold lesions in the rabbit brain. Ultrasound Med Biol. 2001; 27(1): 111-117.
8. Lele PP. Cavitation and its effects on organized mammalian tissues. Amsterdam: Elsevier, 1978.
9. Porter TR, LeVeen RF, Fox R, Kricsfeld A and Xie F. Thrombolytic enhancement with perfluorocarbon-exposed sonicated dextrose aluminous nanoparticles. Am Heart J. 1996; 132(5): 964-968.
10. Tachibana K and Tachibana S. Aluminous microbubble echo-contrast material as an enhancer for ultrasound accelerated thrombolysis. Circulation. 1995; 92: 1148-1150.
11. Hwang JI, Tu J, Brayman AA, Matula TJ and Crum LA. Correlation between internal cavitation dose and endothelial cell damage in vitro. Ultrasound Med Biol. 2006; 32: 1611-1619.
12. Chappell JC, Kilbanov AL and Price RJ. Ultrasound microbubble-induced neovascularization in mouse skeletal muscle. Ultrasound Med Biol. 2005; 31: 1413-1422.
13. Aviv RI, Huynh Y, Huang Y, Ramsay D, Van Slyke P, Dumont D, et al. An in vivo, MRI-integrated real-time model of active contrast extravasation in acute intracerebral hemorrhage. Am J Neuroradiol. 2014; 35(9): 1695-1699.
14. Wood AKW, Ansolini S, Ziemer LS, Lee WMF, Feldman MD and Sehgal CM. The antivascular action of physiotherapy ultrasound on murine tumors. Ultrasound Med Biol. 2003; 31(4): 553-564.
15. Thomas CR, Farny CH and Coussios CC. Dynamics and control of cavitation during high intensity focused ultrasound application. Acoust Lett Online. 2005; 6(3): 182-187.
16. Hockham N, Coussios CC and Arora M. A real-time controller for sustaining thermally relevant acoustic cavitation during ultrasound therapy. IEEE TUFFC. 2010; 57(12): 2685-2694.
17. O’Reilly MA and Hynynen K. Blood-brain barrier: Real-time feedback-controlled focused ultrasound disruption by using an acoustic emissions-based controller. Radiology. 2012; 265(1): 96-106.
18. Lipsman N, Meng Y, Bethune AJ, Huang Y, Lam B, Maselis M, et al. Blood-brain barrier opening in Alzheimer’s disease using MR-guided focused ultrasound. Nat Comm. 2019; 10(1): 2306.
19. Abraham A, Meng Y, Linhas M, Huang Y, Hamami C, Mainprize T, et al. First-in-human trial of blood-brain barrier opening in amyotrophic lateral sclerosis using MR-guided focused ultrasound. Nat Comm. 2019; 10(1): 4573.
20. Mainprize T, Lipsman N, Huang Y, Meng Y, Bethune A, Ironside S, et al. Blood-brain barrier opening in primary brain tumors with noninvasive MR-guided focused ultrasound: A clinical safety and feasibility study. Sci Rep. 2019; 9: 321.
21. Sun T, Zhang Y, Power C, Alexander PM, Sutton JT, Aaryl M, et al. Closed-loop control of targeted ultrasound drug delivery across the blood-brain/tumor barriers in a rat glioma model. Proc Natl Acad Sci USA. 2017; 114(48): E10281-E10290.
22. Dimecvesi G, Kotoopoulos K, Bjesn T, Hoem D, Schijf T, Gjersten BT, et al. A human clinical trial using ultrasound and microbubbles to enhance gemcitabine treatment of inoperable pancreatic cancer. J Control Release. 2016; 243: 172-181.
23. Kotoopoulos S, Dimecvesi G, Gilja OH, Hoem D and Postema M. Treatment of human pancreatic cancer using combined ultrasound, microbubbles and gemcitabine: A clinical case study. Med Phys. 2013; 40: 7.
24. Wang Y, Li Y, Yan K, Shen L, Yang W, Gon J, et al. Clinical study of ultrasound and microbubbles for enhancing chemotherapeutic sensitivity of malignant tumors in digestive system. Chin J Cancer Res. 2018; 30(5): 553-563.
25. Banerji U, Tiu CD, Carucan A, Gurung S, O’Leary M, Bush N, et al. Phase I trials of acoustic cluster therapy (ACT) with chemotherapy in patients with liver metastases of gastrointestinal origin (ACTIVATE study). J Clin Oncol. 2011; 29: 15 Suppl.
26. Rix A, Piepennbrock M, Fliege B, von Stillfried S, Koczer P, Opacic T, et al. Effects of contrast-enhanced ultrasound treatment on neoadjuvant chemotherapy in breast cancer. Theranostics. 2021; 11(19): 9557-9570.
27. McDannold N, Zhang YZ, Power C, Jolesz F and Vykhodtseva N. Nonthermal ablation with microbubble-enhanced focused ultrasound close to the optic tract without affecting nerve function. J Neuroradiol. 2015; 119(5): 1208-1220.
28. Jones RM, McMahon D and Hynynen K. Ultrasound three-dimensional microbubble imaging in vivo predicts tissue damage volume distributions during nonthermal brain ablation. Theranostics. 2020; 10(16): 7211-7220.
29. Todorova M, Agache V, Mortazavi O, Chen B, Karshafian R, Hynynen K, et al. Antitumor effects of combining metronomic chemotherapy with the antivascular action of ultrasound stimulated microbubbles. Int J Cancer. 2012; 132: 2956-2966.
30. Goertz DE, Karshafian R and Hynynen K. Association of cavitation with ultrasound stimulated blood flow modulation in tumours. IEEE IUS: Rome, Italy, 2009.
31. Hu X, Kheirroloomoon A, Mahakian LM, Beegle JR, Kruse DE, Lam KS, et al. Insonation of targeted microbubbles produces regions of reduced blood flow within tumor vasculature. Invest Radiol. 2012; 47(7): 398-405.
32. Goertz DE, Karshafian R and Hynynen K. Antivascular effects of pulsed low intensity ultrasound and microbubbles in mouse tumors. IEEE IUS: Beijing, China, 2008.

https://www.thno.org
35. Wood AK, Schultz SM, Lee WM, Bunte RM and Sehgal CM. Antivascular ultrasound therapy extends survival of mice with implanted melanomas. Ultrasound Med Biol. 2010; 36: 853-857.

36. Wang J, Zhao S, Zhang C, Guo S, Lu Y, et al. Selective depletion of tumor neovascularization by microbubble destruction with appropriate ultrasound pressure. Int J Cancer. 2015; 137: 2478-2491.

37. Liu Z, Gao S, Zhao Y, Li P, Liu J, Li P, et al. Disruption of tumor microvascular endothelial cells by ultrasound: A potential physical therapy anti-angiogenesis. Ultrasound Med Biol. 2012, 38(2): 253-261.

38. Yang J, Zhang XJ, Cai HJ, Chen ZK, Qian QF, Xue ES, et al. Ultrasound-targeted microbubble destruction improved the antiangiogenic efficacy of Endostar in triple-negative breast carcinoma xenografts. J Cancer Res and Clin Oncol. 2015; 141: 1199-1208.

39. Ho YJ, Wang TC, Fan CH and Yeh CK. Current progress in antivascular tumor therapy. Drug Disc Today. 2017; 22(10): 1503-1515.

40. Liu YJ, Wang TC, Fan CH and Yeh CK. Spatial uniform tumor treatment and drug penetration by regulating ultrasound with microbubbles. ACS Appl Mater Interfaces. 2018; 10(21): 17748-17758.

41. Nie F, Xu HX, Lu MD, Wang Y and Tang Q. Anti-angiogenic gene therapy for hepatocellular carcinoma mediated by microbubble-enhanced ultrasound exposure: an in vivo experimental study. J Drug Target. 2008; 16(5): 389-395.

42. Sivapalan N, Leung B and Goertz DE. Combining sorafenib with the antivascular action of microbubbles for the treatment of hepatocellular carcinoma. IEEE IE: Taipei, 2013.

43. Poon C, Proctor A, Garepy J, Hynynen K and Goertz DE. Enhancing checkpoint inhibitor therapy with ultrasound stimulated microbubbles. Ultrasound Med Biol. 2019; 45(2): 500-512.

44. Daecher A, Stanczak M, Liu JB, Zhang J, Du S, Forsberg F, et al. Localized microbubble stimulated-antivascular therapy for improving FUCo treatment response to radiotherapy. Cancer Lett. 2017; 411: 100-105.

45. Lai P, Tarapacki C, Tran WT, El Kaffas A, Lee J, Hulpe C, et al. Breast tumor response to ultrasound-mediated excitation of microbubbles and radiation therapy in vivo. Oncogene. 2013; 32(6): 603-614.

46. Al-Mahrouki AA, Iradji S, Tran WT and Czarnota GJ. Cellular characterization of ultrasound-stimulated microbubble radiation enhancement in a prostate cancer xenograft model. Dis Model Mech. 2014; 7: 363-372.

47. El Kaffas A, Ganges MJ, Farhat G, Tran WT, Hashim A, Giles A, et al. Tumour vascular shutdown and cell death following ultrasound-microbubble enhanced radiation therapy. Theranostics. 2018; 8(2): 314-327.

48. Czarnota GJ, Kasparian R, Burns PN, Wong S, Al-Mahrouki A, Lee JW, et al. Tumor radiological response enhancement by acoustical stimulation of the vasculature. Proc Natl Acad Sci USA. 2012; 109(30): E2033-E2041.

49. Hu S, Zhang X, Unger M, Patties I, Melzer A and Landgraf L. Focused ultrasound-induced cavitation sensitizes cancer cells to radiation therapy and hyperthermia. Cells. 2020; 9: 2095.

50. Tozer GM, Kanthou C and Baguley BC. Disruption of tumour blood vessels. Nat Rev Cancer. 2005; 5(6): 423-435.

51. Hinnen P and Eskenz PALM. Vascular disrupting agents in clinical development. British J Cancer. 2007; 96: 1159-1165.

52. McKeage MJ and Baguley BC. Disrupting established tumor blood vessels: an emerging therapeutic strategy for cancer. Cancer. 2010; 116(8): 1859-1871.

53. Tozer GM, Akerman S, Cross NA, Barber PF, Bjornidal MA, Greco O, et al. Blood vessel maturation and response to targeted therapy in single and metastases. Nat Med. 2016; 22(11): 1294-1302.

54. Huang P, Yang Z, Chen J, Shuntu W, Sun Y, Yang Z, et al. Enhanced antitumor efficacy of ultrasonic cavitation with up-sized microbubbles in pancreatic cancer. Oncotarget. 2015; 6(24): 20421-20425.

55. Arvanitis CD, Vykhodtseva N, Jolese F, Livingstone M and McDanmold N. Cavitatin-enhanced nonthermal ablation in deep brain targets: feasibility in a large animal model. J Neurosurg. 2016; 124(5): 1450-1459.

56. Santos MA, Goertz DE and Hynynen K. Focused ultrasound hyperthermia mediated drug delivery using theromosensitive liposomes and visualized with in vivo two-photon microscopy. Theranostics. 2017; 7(10): 2718-2731.

57. Pellow C, O’Beirly MA, Hynynen K, Zheng G and Goertz DE. Simultaneous intravital optical and acoustic monitoring of ultrasound-triggered nanobubble generation and extravasation. Nano Lett. 2020; 20(6): 4512-4519.

58. Pellow C, Abenjoar EG, Enzer AA, Zheng G and Goertz DE. Concurrent visual and acoustic tracking of passive and active delivery of nanobubbles to tumors. Theranostics. 2020. 10(25): 11690.

59. Drezet MR, Liu W, Michelsh CR, Drehert MW, Yuan F and Chilotti A. Tumor vascular permeability, accumulation, and penetration of macromolecular drug carriers. J Natl Cancer Inst. 2006; 98(5): 335-344.

60. Pries AR, Cornelissen AJM, Shoat AA, Hinkeldey K, Drehet MR, Hopfetet M, et al. Strucural adaptation and heterogeneity of normal and tumor microvascular networks. PLoS Comp Biol. 2009; 5(5): e1000934.

61. Folardet M, Kalmuk J, Lockouet J, Frangou C, Vokes J, Turzowetzet SG, et al. Vascular priming enhances chemotherapeutic efficacy against head and neck cancer. Oral Oncol. 2013; 49(9): 895-902.

62. Nhan T, Burgess A and Hynynen K. Transducer Design and Characterization for Dorsal-Based Ultrasound Exposure and Two-Photon Imaging of In Vivo Blood-Brain Barrier Disruption in a Rat Model. IEEE TUFFC. 2013; 67(6): 1376-1385.

63. Zhao X, Wrightet A and Goertz DE. An optical and acoustic investigation of microbubble cavitation in small vessels under conditions relevant to vascular disruption therapy. Submitted to Ultrasound Sonomed. 2022.

64. Eisenberet JF, Forsberet F, Wessnete CE, Delaney LJD, Brudanet K, Gummadeti S, et al. US-triggered microbubble destruction for augmenting hepatic carcinoma response to transarterial radioembolization. Radiology. 2021; 298(2): 450-457.

65. Bazan-Perezgero AM, Arvanitis CD, Riafet B, Seymour LW and Cossuet CC. Ultrasound-induced cavitation enhances the delivery and therapeutic efficacy of an oncolytic virus in an in vivo model. J Control Release. 2012; 157(2): 235-242.

66. Bazan-Perezgero AM, Riafet B, Carlisetec LC, Choi J, Arvanitis CD, Seymour LW, et al. Cavitation-enhanced delivery of a replicating oncolytic adenovirus to tumors using focused ultrasound. J Control Release. 2009; 137(2): 235-242.

67. Raymond SB, Skochet J, Hynynen K and Backset BJ. Multiphoton imaging of ultrasound/Option mediated cerebrovascular effects in vivo. J Cereb Blood Flow Metab. 2007; 27: 393-403.

68. Tozer C, Pellow C and Hynynen K. Neutrophil recruitment and leukocyte response following focused ultrasound and microbubble mediated blood-brain barrier treatments. Theranostics. 2021; 11(4): 1655.

69. Qin S and Ferraré KWA. Acoustic response of compliant microvessels containing ultrasound contrast agents. Phys Med Biol. 2016; 51(20): 5003-5008.

70. Kascey CF, Steiger SM, Qin S, Dayton PA and Ferraré KWA. Direct observations of ultrasound microbubble contrast agent interaction with the microvascular wall. J Acoust Soc Am. 2007; 122: 1119.

71. Tozer GM, Prise VE, Wilson J, Cemaraset M, Shan S, Dewhirst MW, et al. Mechanisms associated with tumor vascular shutdown induced by combretastatin A-4-phosphate: Intravital microscopy and measurement of vascular permeability. Cancer Res. 2001; 61: 6413-6422.

72. Kobayashi N, Yasa T, Yamada S, Kudo N, Kuroki M, Kawakamiset M, et al. Endothelial cell injury in venule and capillary induced by contrast microbubble cavitation. J Biomed Opt. 2009; 14(1): 014017.

73. Dallecket D, Childt SZ, Raemeet C, Xing C, Gracesetki S and Carstenlet EL. Bioeffects of positive and negative acoustic pressures in mice infused with murine tumor cells. J Acoust Soc Am. 2012; 131(5): 2122-2127.

74. Proserpette et A, Crum LA and Commander KW. Nonlinear bubble dynamics. J Acoust Soc Am. 1988; 83: 502.

75. Johnston K, Tapia-Siles C, Gereldt B, Postemata M, Cochcran S, Cusciereti A, et al. Periodic shock-emission from acoustically driven cavitation clouds: A source of the subharmonic signal. Ultrasound Med Biol. 2014; 40(8): 2151-2158.

76. Sassaeceti O and Hynynen K. On the impact of vessel size on the threshold of bubble collapse. Appl Phys Lett. 2006; 89: 123901.
91. Chen H, Brayman AA, Kreider W, Bailey MR and Matula TJ. Observations of translation and jetting of ultrasound-activated microbubbles in mesenteric microvessels. Ultrasound Med Biol. 2011; 37: 2139-2148.
92. K. Kierzun. Ultrasound-stimulated microbubble induced fluid transport in poroviscohyperelastic media. University of Toronto, MSc Thesis. 2022.
93. O’Reilly MA and Hynynen K. A super-resolution ultrasound method for brain vascular mapping. J Neurosurg. 2011; 114(6): 1654-1661.
94. Liu HL, Hsieh HY, Lu LA, Kang CW, Wu MF and Lin CY. Low-pressure pulsed focused ultrasound with microbubbles promotes an antitumor immunological response. J Transl Med. 2012; 10(221): 1479-5876.
95. Yang Y, Bai W, Chen Y, Lin Y and Hu B. Optimization of low-frequency low-intensity ultrasound-mediated microvessel disruption on prostate cancer xenografts in nude mice using an orthogonal experimental design. Oncol Lett. 2015; 10(5): 2999-3007.
96. He Y, Yu M, Wang J, Xu F, Zong J, Yang Y, et al. Improving the therapeutic effect of ultrasound combined with microbubbles on muscular tumor xenografts with appropriate acoustic pressure. Front Pharmacol. 2020; 11: 1057.
97. Keller SB, Suo D, Wang YN, Kenerson H, Yeung RS and Averkiou MA. Image-guided treatment of primary liver cancer in mice leads to vascular disruption and increased drug penetration. Front Pharmacol. 2020; 11: 584344.